SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms Inc. is experiencing a sharp sell-off as investors react to unfavorable court rulings regarding addictive content and rising concerns over heavy AI capital expenditure. The community is actively debating whether this decline represents a major buying opportunity due to strong fundamentals or a deeper structural shift in social media regulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to volatility driven by reports of Google's new memory compression technology, which some fear could reduce future demand for traditional memory chips. The community remains deeply divided, with many bulls highlighting the company's strong fundamentals and critical role in the AI supply chain, while others are caught in a broader market sell-off triggered by geopolitical tensions and concerns over cyclicality.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing renewed positive momentum driven by a strategic ad partnership with Pacvue that expands its enterprise-scale advertising capabilities. Investors are closely watching ongoing insider buying, which appears to be tempering concerns surrounding previous executive stock sales.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing extreme volatility as traders grapple with escalating geopolitical tensions and erratic energy markets, fueling intense community debate over whether to buy the dip or prepare for further downside. Investors are closely monitoring potential diplomatic developments regarding the Strait of Hormuz, with the discourse split between those aggressively scalping the swings and others cautioning that leveraged semi-conductor exposure remains a risky play amidst broader economic uncertainty.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors eye its dual GLP-1/GIP agonist, VK2735, as a high-potential challenger in the multibillion-dollar obesity market. The community remains focused on upcoming trial milestones, viewing the stock as a prime acquisition target due to its clinical progress and clean profile relative to competitors.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is surging after the GLOW2 Phase 3 study for its eye drug, Zenkuda, met primary endpoints with superior results compared to sham treatment. The community is actively discussing a potential short squeeze due to high short interest, while debating whether the current move marks a long-term rerating of the company's platform or a temporary spike prone to profit-taking.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is seeing heightened investor attention and a strong upward trend, driven by robust commercial execution of its lead therapy, Rezdiffra, and speculation regarding potential long-term acquisition interest from major biopharma players. While the community is actively debating the company's high operating expenses versus its market leadership in the MASH space, technical momentum and positive analyst coverage continue to fuel significant bullish sentiment.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is experiencing heightened market attention following a volatile reaction to interim clinical data for its obesity candidate, WVE-007, which has sparked intense debate over its long-term potential compared to GLP-1 incumbents. While some investors are bullish on the company's RNA-based platform and its unique ability to reduce visceral fat while preserving muscle mass, others remain skeptical about the trial design and are wary of potential further downside as analysts balance ambitious price targets against the challenges of a crowded obesity pipeline.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are reacting negatively to a recent reverse stock split, with many in the community expressing extreme frustration over a lack of communication from management and a sharp decline in share price. Discussion is dominated by concerns over the company's long-term viability, allegations of market manipulation, and intense debate regarding whether the stock is an oversold buying opportunity or a value trap heading toward bankruptcy.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high AI capital expenditures and a potential slowdown in software revenue growth, leading to a persistent decline in share price. The community is deeply divided between those viewing the current drop as an oversold, generational buying opportunity and those fearing a deeper structural breakdown in the stock's long-term momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Barclays analyst Tom O'Malley raised the firm's price target on Arm to $200 from $165 and kept an ‘Overweight’ rating on the shares.</li><li>RBC Capital said that Arm’s much-anticipated full-chip strategy will complement its IP business.</li><li>Arm on Tuesday had announced that it is extending into&nbsp;the&nbsp;production of silicon products for the first time in its history.&nbsp;</li></ul>Shares of Arm Holdings (ARM) closed 16% higher on Wednesday as several analysts were buoyed by the company's outlook as well as its first company-designed data center CPU.&nbsp;Arm on Tuesday had announced that it is extending into&nbsp;the production of silicon products for the first time in its history with the launch of the Arm AGI CPU, an Arm-designed CPU for AI data centers, built to address a rising class of agentic AI workloads.Arm CEO Rene Haas reportedly told Bloomberg in an interview on Tuesday that the company expects its own chips business to generate about $15 billion in annual sales in five years. Meta Platforms (META) will be the first major customer for the company's new AGI CPU chip.<h2 class="st-heading-2">Bullish Wall Street</h2>Raymond James&nbsp;subsequently upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's announced business model shift to include a fabless semiconductor element for the upgrade, per TheFly.&nbsp;Barclays analyst Tom O'Malley raised the firm's price target on Arm to $200 from $165 and kept an ‘Overweight’ rating on the shares. The "Arm Everywhere" event made it clear that CPUs play a very important role in agentic AI and the company's solution is the AGI CPU, which "plays to ARM's strength in energy efficiency," the analyst told investors.RBC Capital also raised the firm's price target on Arm to $175 from $130 and kept an ‘Outperform’ rating on the shares. The firm cited the company's much-anticipated full-chip strategy, which the management believes will complement its IP business, the analyst told investors in a research note. The strategy offers significant revenue growth and earnings potential over the long term but comes with gross margin dilution and channel conflict issues, RBC Capital added.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around ARM trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have risen 39% so far in 2026.&nbsp;

The replica of the ARM is an electronic chip board during a collaborative ceremony launching a partnership between Malaysia and ARM Holdings in Kuala Lumpur, Malaysia, on March 5, 2025. 

Why Did Arm Stock Close 16% Higher Today?

Raymond James upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's business model shift to include a fabless semiconductor element for the upgrade.

Equity

Raymond James upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's business model shift to include a fabless semiconductor element for the upgrade.


<ul class="summary-bullets"><li>BTIG reiterated a ‘Buy’ rating and $70 price target on On Holding.</li><li>Telsey Advisory analyst Cristina Fernandez lowered the firm's price target on On Holding to $60 from $65.</li><li>Co-founder Olivier Bernhard will continue spearheading key performance product initiatives and athlete engagement as an Executive Member of the Board.</li></ul>ON Holdings (<a href="https://stocktwits.com/symbol/ONON">ONON</a>) shares were down nearly 11% on Wednesday after its CEO Martin Hoffmann&nbsp;stepped down from his role,&nbsp;bringing the stock into analysts' focus.&nbsp;Telsey Advisory analyst Cristina Fernandez lowered the firm's price target on On Holding to $60 from $65 and kept an ‘Outperform’ rating on the shares.BTIG reiterated a ‘Buy’ rating and $70 price target on On Holding. After speaking with the company, the firm said it does not believe the change in leadership is reflective of any challenges in the current business, but rather a transition that coincides with its next phase of growth currently being formulated and Hoffmann's desire to pursue more personal interests.&nbsp;Management stressed this decision is not correlated with how the current business is doing and their excitement regarding the year ahead is "as high as ever," the analyst told investors in a research note.<h2 class="st-heading-2">New Co-CEOs</h2>The company said that David Allemann and Caspar Coppetti will assume the roles of Co-CEOs, while continuing as Executive Co-Chairmen of the Board. Co-founder Olivier Bernhard will continue spearheading key performance product initiatives and athlete engagement as an Executive Member of the Board.“With the strategic roadmap for continued growth in place, the four partners collectively recognize that this is the right moment for Martin Hoffmann to step down,” the company said in regards to Hoffman’s stepping down.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around ONON trended in ‘extremely bullish’ territory amid ‘high’ message volume.Shares in the company have fallen 25% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of On Holding AG (NYSE: ONON), a Swiss sportswear company known for its high-performance running shoes and apparel. 

ONON Stock Falls After Surprise CEO Resignation Leaves Wall Street Divided

The company said that David Allemann and Caspar Coppetti will assume the roles of Co-CEOs, while continuing as Executive Co-Chairmen of the Board.

<ul class="summary-bullets"><li>Amid rumors, the companies confirmed the deal to WSJ early Friday.&nbsp;</li><li>Unilever’s food business is said to be worth tens of billions of dollars, and the deal with McCormick would involve only stock and no cash - WSJ source.</li><li>Stocktwits sentiment for UL and MKC ‘bullish.’</li></ul>U.S.-listed shares of Unilever PLC jumped 2.3% in early premarket trading on Friday, amid news of a restructuring involving its food business.The packaged goods giant plans to separate its foods business, which includes Knorr soups, Hellmann’s mayonnaise and Lipton tea, among other items, and combine it with spice&nbsp;maker&nbsp;McCormick, the companies&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/unilever-in-talks-to-separate-food-business-and-combine-it-with-mccormick-212091ae">confirmed</a> to the Wall Street Journal.&nbsp;McCormick shares rose 1% in Friday’s premarket session.<h2 class="st-heading-2">Unilever Sharpen Focus On Beauty, Personal Care</h2>The major strategy shift by Unilever would continue a trend of consumer conglomerates streamlining their businesses and would leave U.K.-based Unilever focused on beauty, personal-care products and home, the Journal reported.Unilever’s food business is said to be worth tens of billions of dollars, and the deal with McCormick would involve only stock and no cash, the Journal reported, citing information from a source.Maryland-based McCormick, known for its bottled spices and brands like French’s yellow mustard, is set to report its first-quarter results on March 31.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/UL">UL</a> and&nbsp;<a href="https://stocktwits.com/symbol/MKC">MKC</a> was ‘bullish’ early Friday.<h2 class="st-heading-2">Consumer Conglomerates Eye Deals&nbsp;</h2>Trian Fund Management’s Nelson Peltz joined Unilever’s board in 2022 after the hedge fund took a big stake in the company. The activist investor was previously a director at Unilever rival Procter &amp; Gamble, and has a record of pushing for splits and reconfigurations of sprawling conglomerates.Unilever spun off its ice cream business, Magnum Ice Cream, last year. In 2021, the company made unsolicited approaches to GlaxoSmithKline’s consumer-health unit but backed off the idea the following year.Kraft Heinz last year unveiled plans to split into separate companies, reflecting a broader “<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/kraft-heinz-is-splitting-into-two-companies-2b632fa7?mod=article_inline">conglomerate breakup</a>” trend gaining traction across the consumer sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smci-stock-cracks-premarket-on-alleged-nvidia-chip-diversion-to-china-super-micro-nvda-stress-compliance/cZ3XjzQRIh6">SMCI Stock Cracks Premarket On Alleged Nvidia Chip Diversion To China; Super Micro, NVDA Stress Compliance</a>&nbsp;

Hellmann's Mayonnaise seen at a supermarket. (Photo by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

UL, MKC Stocks Jump Premarket: McCormick Reportedly Confirms Buying Unilever’s Food Business

The Journal reported that the deal could be announced in the coming weeks.

SPDW, EFZ: Big ETF Inflows

Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the SPDR Portfolio Developed World ex-US ETF, which added 22,800,000...

International ETFs to Watch as Foreign Stock Markets Beat the US

International stocks crushed U.S. markets in 2025, with ETFs such as SPDW and JIVE emerging as top plays on the global shift.

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.<h2 class="st-heading-2">Executive Takeaway</h2>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”<stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.<stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

<ul class="summary-bullets"><li>Baytex Energy announced a target of 3% to 5% annual production growth, targeted to reach about 75,000 boe/d in 2028.&nbsp;</li><li>The company said it plans to return a significant portion of Eagle Ford’s $2.14 billion in sale proceeds to shareholders.&nbsp;</li><li>It appointed Chad E. Lundberg as the President and Chief Operating Officer from Dec. 22, 2025.</li></ul>Baytex Energy Corp. (BTE) is setting the stage for growth in 2026 with a $625 million capital budget and plans to return a significant part of its Eagle Ford sale proceeds to shareholders. Additionally, the announcement of a new leadership signals a shift in priorities for the year ahead.Shares of BTE climbed over 2% in Monday's pre-market trade.<h2 class="st-heading-2">Capital Budget Usage</h2>Baytex Energy announced a capital budget of $550 to $625 million for 2026, a target of 3% to 5% production growth reaching about 75,000 barrels of oil equivalent per day (boe/d) in 2028.The company’s 2026 exploration and development budget aims to generate an average annual production of 67,000 to 69,000 boe/d and is expected to deliver 3% to 5% production growth from 2025 levels.Of this, about 55% of the budget will be allocated to light oil assets, and the remaining 45% to heavy oil assets, the company said. Production in the first quarter (Q1) of 2026 is expected to average 68,000 to 69,000 boe/d, with plans to scale to 70,000 boe/d at the end of the year. The company also plans to bring 91 heavy-oil wells onstream, with 2026 production averaging 43,000 to 44,000 bbl/d.Of the total capital expenses, $50 to $75 million growth capital will be focused on the Pembina Duvernay and northeast Alberta Mannville, $50 million will be directed towards infrastructure investment that will include anchor oil batteries and water infrastructure in the Pembina Duvernay, and gas conservation in Peace River, and another $50 million will go towards exploration and land investments, the company said."Looking ahead, we are targeting 3% to 5% annual production growth while investing in exploration and infrastructure for future development. Supported by our industry-leading net cash balance sheet, we are prioritizing shareholder returns in 2026," Eric T. Greager, Chief Executive Officer of Baytex Energy, said.<h2 class="st-heading-2">Sale Proceeds And Executive Charges</h2>Baytex Energy completed the sale of its U.S. Eagle Ford Assets for $2.14 billion on December 19, and plans to return a significant portion of the proceeds to shareholders.The company also reaffirmed its annual dividend guidance of $0.09 per share, subject to Board of Directors approval.Additionally, the energy company announced that Chad E. Lundberg will take over as President and Chief Operating Officer from Dec. 22, 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1291/159;" src="https://news.stocktwits-cdn.com/Baytex_sentiment_png_47e2fce461.webp" alt="On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing." width="1291" height="159"></figure>Shares of BTE have gained over 25% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/09/17: In this photo illustration, the Baytex Energy Corp. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Baytex Energy Sets 2026 Capital Spending, Growth Targets – And Names New COO

The company announced a capital budget of up to $625 million for 2026, with 55% allocated to light oil assets and 45% to heavy oil assets.

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

SPDR Index Shares Funds - State Street SPDR Portfolio Developed World ex-US ETF

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF